Targeted screening for Barrett's esophagus and esophageal cancer: Post-hoc analysis from the randomized BEST3 trial

Gastroenterology. 2024 May 6:S0016-5085(24)00495-5. doi: 10.1053/j.gastro.2024.04.030. Online ahead of print.

BEST3 Trial Team:
Massimiliano di Pietro¹, Maria O'Donovan¹, Beth Muldrew¹, Irene Debiram-Beecham¹, Marcel Gehrung¹, Monika Tripathi¹, Samuel G Smith¹, Benoit Aigret¹, Fiona M Walter¹, Greg Rubin¹, Peter D Sasieni⁴, Rebecca C Fitzgerald¹

¹ Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
² King's College London Cancer Prevention Trials Unit, Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, UK.
³ Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ; School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
⁴ King's College London Cancer Prevention Trials Unit, Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, King's College London, Innovation Hub, Guys Cancer Centre, Guy's Hospital, Great Maze Pond, UK; Centre for Cancer Screening, Prevention, and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London EC1M 6BQ.

No abstract available